The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin–the Aprepitant Protocol 052 Study Group - Hesketh, P J; Grunberg, S M; Gralla, R J; Aprepitant Protocol 052 Study Group (J Clin Oncol, 2003)